Guided by the field's
leading researchers.

Dr. Boyle's research applies quantitative pharmacology and clinical trial design to optimize drug therapy in pediatric patients undergoing chemotherapy, immunosuppression, hematopoietic cell transplantation, and gene therapy. Her work focuses on reducing the technical barriers to implementing population pharmacokinetic models in routine clinical practice for children with life-threatening disease.

Dr. Savic’s research uses computational methods to study the dynamic interplay between disease progression, drug and biomarker response across relevant scales (molecule, cell, tissue, organ and whole body) in order to determine causal links underlying variability in (safety and efficacy) clinical outcomes. Her goal is to determine the optimal dosage, timing, and duration of therapeutic regimens and ultimately develop precise, personalized treatments.

Dr. Peck has over 30 years of experience as a clinical pharmacologist at Glaxo Wellcome, Eli Lilly, and Roche. At Hoffmann-La Roche, his group defines dosing and explores response variability for small and large molecules across development and regulatory approval. His current research focuses on identifying precision dosing algorithms in early clinical development that can be tested in pivotal pre-approval trials. He holds a medical degree from St. John's College, Cambridge, and practiced as a hospital physician before moving into clinical pharmacology.

Dr. Rybak is an experienced Professor of Pharmacy and Medicine with an extensive history of working in higher education with a focus in antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious disease health outcomes, including their relationship to bacterial resistance.

Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing and informatics technologies to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels.

Dr. Neely is Director of the USC Laboratory of Applied Pharmacokinetics and Bioinformatics and a Professor of Pediatrics at USC and Children's Hospital of Los Angeles. His research spans pediatric clinical pharmacometrics, population PK/PD modeling, pharmacogenomics, and simulation — with a focus on using models to optimize therapy for individual patients.

Grace brings over 25 years of medical device industry experience, including 15+ years in startups from initial funding to full operations. She has led quality, regulatory, and clinical teams across a broad range of projects including 510(k), PMA, CE, and Canadian applications, Design History File and Device Master Record preparation, multi-site clinical studies, Quality System establishment and audits, FDA and Notified Body inspections, device verification and validation, software tool validation for 21 CFR 11 compliance, and process validation.

Ashfaq is a Senior Technology Executive with broad and deep technical and business knowledge along with proven ability to motivate teams and deliver results at scale. He is a deeply strategic thinker able to quickly synthesize data and transform it into market opportunity and competitive advantage. Ashfaq is also an ML7 fellow at the University of Toronto’s Joseph L. Rotman School of Management.